4-(3-chloropropoxy)benzoic acid methyl ester | 69076-29-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(3-chloropropoxy)benzoic acid methyl ester
• 英文别名: methyl 4-(3-chloropropoxy)benzoate；methyl 4-[(3-chloropropyl)oxy]benzoate；4-(3-chloro-propoxy)-benzoic acid methyl ester；4-(3-Chlor-propoxy)-benzoesaeure-methylester；4-(3-chloropropoxy)benzoic acid, methyl ester；4-(3-chloropropoxy)benzoic acid,methyl ester
• CAS: 69076-29-5
• 化学式: C₁₁H₁₃ClO₃
• 分子量: 228.675
• InChiKey: OMNGJGSAPWWSHP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  15
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(3-chloropropoxy)benzoic acid methyl ester 在 aluminum (III) chloride 、 氯化亚砜 、 水 、 potassium carbonate 、 sodium hydroxide 作用下， 以 N-甲基吡咯烷酮 、 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 氯苯 为溶剂， 反应 34.0h， 生成 决奈达隆
  参考文献：
  名称：

  Process for preparing dronedarone

  摘要：

  本发明涉及一种制备多奈达鲁酮的方法，特别是用于制备多奈达鲁酮制备中间体的方法。此外，本发明还涉及一种制备结晶多奈达鲁酮盐酸盐的方法，以及包含该盐的药物组合物。

  公开号：

  EP2371808A1
• 作为产物：
  描述：

  1,3-二氯丙烷 、 对羟基苯甲酸甲酯 在 sodium ethanolate 作用下， 生成 4-(3-chloropropoxy)benzoic acid methyl ester
  参考文献：
  名称：

  Phenoxy- and Benzyloxyalkyl Thiocyanates¹

  摘要：

  DOI：

  10.1021/ja01151a047

文献信息

• Npy antagonists, preparation and uses
  申请人：Botez Iuliana

  公开号：US20090233910A1

  公开（公告）日：2009-09-17

  The present invention concerns novel compounds, their preparation and their uses, therapeutic uses in particular. More specifically it concerns derivative compounds having at least two aromatic cycles, their preparation and their uses, in particular in the area of human or animal health. These compounds have an affinity for the biological receptors of neuropeptide Y, NPY, present in the central and peripheral nervous systems. The compounds of the invention are preferably NPY antagonists, and more particularly antagonists of sub-type NPY Y1, and can therefore be used for the therapeutic or prophylactic treatment of any disorder involving NPY. The present invention also concerns pharmaceutical compositions containing said compounds, their preparation and their uses, as well as treatment methods using said compounds.

  本发明涉及新颖化合物，它们的制备和用途，特别是在治疗方面的用途。更具体地说，它涉及至少具有两个芳香环的衍生化合物，它们的制备和用途，特别是在人类或动物健康领域。这些化合物对存在于中枢和外周神经系统中的神经肽Y（NPY）的生物受体具有亲和力。本发明的化合物优选为NPY拮抗剂，更具体地说是NPY Y1亚型的拮抗剂，因此可用于治疗或预防涉及NPY的任何疾病。本发明还涉及含有所述化合物的药物组合物，其制备和用途，以及使用所述化合物的治疗方法。
• Synthesis and antiallergy activity of 4-(diarylhydroxymethyl)-1-[3-(aryloxy)propyl)piperidines and structurally related compounds
  作者：David A. Walsh、Stephen K. Franzyshen、John M. Yanni

  DOI：10.1021/jm00121a022

  日期：1989.1

  A series of 4-(diarylhydroxymethyl)-1-[3-(aryloxy)propyl]piperidines was synthesized and evaluated for antiallergy activity. Several analogues had potent activity in the passive foot anaphylaxis (PFA) assay, an IgE-mediated model useful in the detection of compounds possessing antiallergic activity. In particular 1-[4-[3-[4-[bis(4-fluorophenyl)hydroxymethyl]-1-piperidinyl] propoxy]-3-methoxyphenyl]ethanone

  合成了一系列的4-（二芳基羟甲基）-1- [3-（芳氧基）丙基]哌啶，并评估了其抗过敏活性。几种类似物在被动足过敏症（PFA）检测中具有有效活性，PFA检测是一种IgE介导的模型，可用于检测具有抗过敏活性的化合物。特别是1- [4- [3- [4- [双（4-氟苯基）羟甲基] -1-哌啶基]丙氧基] -3-甲氧基苯基]乙酮（1，AHR-5333）比奥沙米特和特非那定在这种测定。
• Arylalkylheterocyclic amines,N-substituted by aryloxyalkyl group in a
  申请人：A. H. Robins Company, Incorporated

  公开号：US04950674A1

  公开（公告）日：1990-08-21

  A method of inhibiting Type 1 allergic responses in a living animal body with substituted heterocyclic amines is disclosed wherein the active agents are expressed generally by the formula which includes certain known and certain known compounds: ##STR1## wherein P is zero, one or two; m is one to six inclusive; A is selected from hydrogen, hydroxy or cyano; d is zero or one; Q is --CH--, CH.sub.2 -- or ##STR2## n is zero or one and when Q is --CH-- and n is one, a double bond is formed with one of the adjacent carbons but not both at the same time, and when n and d are zero at the same time, a double bond is formed between the .alpha. carbon and a carbon of the central heterocyclic amine ring; Ar, D and R are selected from phenyl, substituted phenyl, pyridinyl, thienyl, furanyl or naphthyl and in addition, R may have the values benzyl, substituted benzyl, cycloalkyl or loweralkyl and D may additionally have the values: 2H-1-benzopyran-2-one,4-oxo-4H-1-benzopyran-2-carboxylic acid loweralkyl ester, 2,3-dihydro-4H-1-benzopyran-4-one, 1,4-benzodioxanloweralkyl-2-yl or 1,1'-biphenyl-4-yl and the pharmaceutically acceptable salts thereof.

  揭示了一种利用取代杂环胺抑制活体动物体内的1型过敏反应的方法，其中活性剂通常由以下公式表示：其中P为零、一或二；m为一到六（包括六）；A选自氢、羟基或氰基；d为零或一；Q为--CH--、CH.sub.2--或n为零或一，当Q为--CH--且n为一时，与相邻碳之一形成双键，但不同时与两个相邻碳形成双键；当n和d同时为零时，在中心杂环胺环的α碳和一个碳之间形成双键；Ar、D和R选自苯基、取代苯基、吡啶基、噻吩基、呋喃基或萘基，此外，R可能具有苄基、取代苄基、环烷基或较低烷基的值，D还可能具有以下值：2H-1-苯并吡喃-2-酮、4-氧代-4H-1-苯并吡喃-2-羧酸较低烷基酯、2,3-二氢-4H-1-苯并吡喃-4-酮、1,4-苯并二氧杂环较低烷基-2-基或1,1'-联苯基-4-基，以及其药学上可接受的盐。
• Phenylcarboxylic acid derivatives
  申请人：Otsuka Pharmaceutical Company, Limited

  公开号：US04999378A1

  公开（公告）日：1991-03-12

  Phenylcarboxylic acid derivatives having the formula: ##STR1## wherein R.sup.1 and R.sup.2 are each H, halogen, alkyl, haloalkyl, alkanoyl, cycloalkyl, nitro, amino, --O--D--R.sup.5 (D is alkylene, R.sup.5 is H, amino, morpholino, carboxyl, phthalimido, phenyl, epoxy), substituted or unsubstituted phenoxy, substituted or unsubstituted phenylalkylamino, carboxylalkenyl, or both form alkylenedioxy; R.sup.3 is H, --E--R.sup.6 (E is alkylene, R.sup.6 is H, carboxyl, cyano, OH, phenylalkoxy, or halogen-substituted phenyl, or phenylcarbamoyl), --CO--G--R.sup.7 (G is alkylene, R.sup.7 is H, substituted or unsubstituted phenylcarbamoyl), substituted or unsubstituted benzoyl, alkenyl, carbamoyl, phenyl, or halophenyl; R.sup.4 is H or alkyl; A is alkylene, alkylene condensed with cycloalkyl ring, or alkenylene; B is alkylene or alkenylene; l is 0 or 1. Said compounds have fatty acid synthesis-inhibitory activity, cholesterol synthesis-inhibitory activity and are useful as antilipidemic agent, prophylactic and treating agent of artherosclerosis, prophylactic and treating agent of obesity, antidiabetics.

  苯甲酸衍生物，具有以下通式：##STR1## 其中R1和R2各自为H、卤素、烷基、卤代烷基、烷酰基、环烷基、硝基、氨基、--O--D--R5（D为亚烷基，R5为H、氨基、吗啉基、羧基、邻苯二甲酰亚胺、苯基、环氧基）、取代或未取代的苯氧基、取代或未取代的苯基烷基氨基、羧基烯基，或两者共同形成亚烷基二氧；R3为H、--E--R6（E为亚烷基，R6为H、羧基、氰基、OH、苯基烷氧基、或卤素取代的苯基，或苯基氨基甲酰基）、--CO--G--R7（G为亚烷基，R7为H、取代或未取代的苯基氨基甲酰基）、取代或未取代的苯甲酰基、烯基、氨基甲酰基、苯基、或卤代苯基；R4为H或烷基；A为亚烷基、与环烷基环稠合的亚烷基，或亚烯基；B为亚烷基或亚烯基；l为0或1。这些化合物具有抑制脂肪酸合成、抑制胆固醇合成的作用，并可作为降脂剂、动脉粥样硬化的预防和治疗剂、肥胖的预防和治疗剂、抗糖尿病药物。
• Fibrinogen receptor antagonists
  申请人：Merck & Co., Inc.

  公开号：US05648368A1

  公开（公告）日：1997-07-15

  Novel fibrinogen receptor antagonists of the formula: X--Y--Z--Aryl--A--B are provided in which the claimed compounds exhibit fibrinogen receptor antagonist activity, inhibit platelet aggregation and are therefore useful in modulating thrombus formation.

  提供了一种新型的纤维蛋白原受体拮抗剂，其化学式为：X--Y--Z--芳基--A--B，所述的化合物具有纤维蛋白原受体拮抗活性，能够抑制血小板聚集，因此在调节血栓形成方面具有用途。